Results 11 to 20 of about 70,330 (230)

RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab

BMC Cancer, 2023
Background Radioimmunotherapy with cetuximab and conjugates with various radioisotopes is a feasible treatment option for different tumor models. Scandium-47 (47Sc), one of several β−-particle-emitting radioisotopes, displays favorable physical and ...
Da-Mi Kim, So-Young Lee, Jae-Cheong Lim, Eun-Ha Cho, Ul-Jae Park   +4 more
doaj   +1 more source

Exploring the Application of Bifunctional Metal Chelators in Treating Triple-Negative Breast Cancer

Frontiers in Bioengineering and Biotechnology, 2021
Purpose: In this study, we independently synthesised and labelled a novel bidentate bifunctional chelating agent, 177Lu-3,4-HOPO-Cetuximab, that achieved tight binding between targeting and radioactivity, and evaluated its targeted killing ability of ...
Kuo Li, Kuo Li, Youjiu Zhang, Xiaomei Wang, Ran Zhu, Changsheng Ma, Rui Hu   +6 more
doaj   +1 more source

Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection

World Allergy Organization Journal, 2021
Background: Cetuximab (chimeric monoclonal antibody to human epidermal growth factor receptor) is used to treat colorectal and head and neck cancers. Due to cross-reactivity with galactose-α-1,3-galactose (alpha-gal), it can induce hypersensitivity even ...
Kyung Hee Park, Jongsun Lee, Seung Hoon Beom, Sang Joon Shin, Joong Bae Ahn, Sung-Ryeol Kim, Jae-Hyun Lee, Jung-Won Park   +7 more
doaj   +1 more source

Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.

PLoS ONE, 2020
The epidermal growth factor receptor inhibitor cetuximab is the only oncogene-targeted agent that has been FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC).
Rachel A O'Keefe, Neil E Bhola, David S Lee, Daniel E Johnson, Jennifer R Grandis   +4 more
doaj   +1 more source

Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials [PDF]

, 2012
Purpose: This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC).
Allegra CJ, Amado RG, Andreas Jung, Andreyev HJ, Bazan V, Bokemeyer C, Bos JL, Boughdady IS, Cappuzzo F, Cerottini JP, Christoph C. Zielinski, De Roock W, Dominik P. Modest, Douillard JY, Finkelstein SD, Frattini M, Galina Kurteva, Heinemann V, Janja Ocvirk, Jens Neumann, Jonker DJ, Karapetis CS, Khambata-Ford S, Khosravi-Far R, Lièvre A, Maughan TS, Moosmann N, Neumann J, Ocvirk J, Regina Knittelfelder, Roth AD, Ruediger P. Laubender, Samowitz WS, Scheffzek K, Sebastian Stintzing, Thomas Brodowicz, Thomas Kirchner, Tournigand C, Tveit K, Van Cutsem E, Volker Heinemann, Zsuzsanna Papai   +41 more
core   +1 more source

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab [PDF]

, 2015
Background: The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients' clinical outcome more accurately than RAS status alone.
Abouelkhair, KM, Cascinu, S, Del Prete, M, Faloppi, L, Giampieri, R, Ibrahim, EM, Loretelli, C, Mandolesi, A, Maristella, B, Scarpelli, M, Scartozzi, M   +10 more
core   +3 more sources

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. [PDF]

, 2018
BackgroundThe value of induction chemotherapy (ICT) remains under investigation despite decades of research. New advancements in the field, specifically regarding the induction regimen of choice, have reignited interest in this approach for patients with
Cohen, EEW, Haddad, RI, Hitt, R, Lefebvre, J-L, Posner, M, Schulten, J, Vermorken, JB   +6 more
core   +1 more source

Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors [PDF]

, 2019
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic ...
Aderka, Dan, García Foncillas, Jesús, Ronga, Philippe, Stintzing, Sebastian, Sunakawa, Yu, Wainberg, Zev, Witzler, Pauline   +6 more
core   +1 more source

Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer

Cell Death and Disease, 2021
Cetuximab is approved for the treatment of metastatic colorectal cancer (mCRC) with RAS wild-type. Nevertheless, the prognosis remains poor and the effectiveness of cetuximab is limited in KRAS mutant mCRC.
Jiawen Yang, Jiajie Mo, Juji Dai, Chenqiao Ye, Wei Cen, Xuzhi Zheng, Lei Jiang, Lechi Ye   +7 more
doaj   +1 more source

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. [PDF]

, 2014
BackgroundAfatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth factor receptor (EGFR)-mutated lung cancer.
Blackman, A, Clement, PM, Cohen, EEW, Cupissol, D, Degardin, M, Del Campo, JM, Ehrnrooth, E, Fayette, J, Hitt, R, Seiwert, TY, Zhang, W   +10 more
core   +2 more sources